Cargando…

Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy

Obesity is the single greatest risk factor for nonalcoholic fatty liver disease (NAFLD). Without intervention, most pediatric patients with NAFLD continue to gain excessive weight, making early, effective weight loss intervention key for disease treatment and prevention of NAFLD progression. Unfortu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friesen, Chance S., Hosey-Cojocari, Chelsea, Chan, Sherwin S., Csanaky, Iván L., Wagner, Jonathan B., Sweeney, Brooke R., Friesen, Alec, Fraser, Jason D., Shakhnovich, Valentina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076784/ https://www.ncbi.nlm.nih.gov/pubmed/33927697 http://dx.doi.org/10.3389/fendo.2021.663351

Ejemplares similares

Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective
por: Friesen, Chance S., et al.
Publicado: (2021)

Are body surface area based estimates of liver volume applicable to children with overweight or obesity? An in vivo validation study
por: Hosey‐Cojocari, Chelsea, et al.
Publicado: (2021)

Pediatric growth patterns in youth‐onset type 2 diabetes mellitus: Implications for physiologically‐based pharmacokinetic models
por: Hosey, Chelsea M., et al.
Publicado: (2022)

Lean nonalcoholic fatty liver disease and sarcopenia
por: Chen, Milian, et al.
Publicado: (2023)

Role of extracellular vesicles in nonalcoholic fatty liver disease
por: Jiang, Wei, et al.
Publicado: (2023)

Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
por: Yang, Bing, et al.
Publicado: (2022)

Corrigendum: Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
por: Yang, Bing, et al.
Publicado: (2023)

Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies
por: Fang, Tingyu, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease in University Rugby Football Players
por: Nirengi, Shinsuke, et al.
Publicado: (2018)

The impact of obstructive sleep apnea on nonalcoholic fatty liver disease
por: Tang, Haiying, et al.
Publicado: (2023)

Emerging Trend in the Pharmacotherapy of Osteoarthritis
por: Zhang, Wei, et al.
Publicado: (2019)

The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease
por: Ryan, Jamie L., et al.
Publicado: (2022)

Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease
por: Zhou, Fangli, et al.
Publicado: (2021)

Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?
por: Tsankof, Alexandra, et al.
Publicado: (2022)

Clinical characterization and proteomic profiling of lean nonalcoholic fatty liver disease
por: Jiang, Yuanye, et al.
Publicado: (2023)

Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms
por: Takahashi, Hirokazu, et al.
Publicado: (2018)

Complex impacts of gallstone disease on metabolic syndrome and nonalcoholic fatty liver disease
por: Lyu, Jingting, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population
por: Ciardullo, Stefano, et al.
Publicado: (2021)

Red Blood Cell Count: An Unrecognized Risk Factor for Nonalcoholic Fatty Liver Disease
por: Zhong, Fang, et al.
Publicado: (2021)

Clinical spectrum transition and prediction model of nonalcoholic fatty liver disease in children with obesity
por: Zhou, Xuelian, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease is specifically related to the risk of hepatocellular cancer but not extrahepatic malignancies
por: Albhaisi, Somaya, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease and type 2 diabetes: an observational and Mendelian randomization study
por: Yu, Yuetian, et al.
Publicado: (2023)

Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy
por: Itoh, Nobuyuki, et al.
Publicado: (2015)

Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zhang, Yuyuan, et al.
Publicado: (2022)

The potential role of lactulose pharmacotherapy in the treatment and prevention of diabetes
por: Chu, Natural, et al.
Publicado: (2022)

Long-chain saturated fatty acids and its interaction with insulin resistance and the risk of nonalcoholic fatty liver disease in type 2 diabetes in Chinese
por: Jiang, Li-Peng, et al.
Publicado: (2022)

Associations Between Abdominal Obesity Indices and Nonalcoholic Fatty Liver Disease: Chinese Visceral Adiposity Index
por: Chen, Xueyu, et al.
Publicado: (2022)

Diagnostic performance of novel inflammatory biomarkers based on ratios of laboratory indicators for nonalcoholic fatty liver disease
por: Zhao, Yanhua, et al.
Publicado: (2022)

The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: A dose–response meta-analysis
por: Ling, Qin, et al.
Publicado: (2023)

Causal effects of nonalcoholic fatty liver disease on cerebral cortical structure: a Mendelian randomization analysis
por: Mai, Zhiliang, et al.
Publicado: (2023)

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
por: Tan, Qiming, et al.
Publicado: (2022)

Association of Nonalcoholic Fatty Liver Disease With Osteoporotic Fractures: A Cross-Sectional Retrospective Study of Chinese Individuals
por: Wang, Yanmao, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease in children with obesity– observations from one clinical centre in the Western Pomerania region
por: Marcinkiewicz, Katarzyna, et al.
Publicado: (2022)

Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma: An emerging therapeutic strategy
por: Huang, Chen, et al.
Publicado: (2023)

Serum IL-27 levels increase in subjects with hypothyroidism and are negatively correlated with the occurrence of nonalcoholic fatty liver disease
por: Wen, Yahui, et al.
Publicado: (2023)

Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma
por: Hwang, Yoon-a, et al.
Publicado: (2023)

Long Working Hours and Risk of Nonalcoholic Fatty Liver Disease: Korea National Health and Nutrition Examination Survey VII
por: Song, Eyun, et al.
Publicado: (2021)

Exercise inhibits JNK pathway activation and lipotoxicity via macrophage migration inhibitory factor in nonalcoholic fatty liver disease
por: Cui, Ni, et al.
Publicado: (2022)

Transcriptomic profiling of hepatic tissues for drug metabolism genes in nonalcoholic fatty liver disease: A study of human and animals
por: Chen, Li, et al.
Publicado: (2023)

Causal relationship between nonalcoholic fatty liver disease and different sleep traits: a bidirectional Mendelian randomized study
por: Sun, Zijin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v8ha2v9lrs4ejdjsj8f3ooh15b